The Multi-State Stem Cell Law Map: Where Your State Stands in June 2026
Until 2017, no U.S. state had a law specifically addressing non-FDA-approved stem cell therapy at the provider level. Since California broke that ground, the count has grown to at least half a dozen states with disclosure or authorization frameworks, and the pace is accelerating: Florida, Utah, and Wyoming all enacted or expanded frameworks across 2025 […]
Nevada’s Approach to Unapproved Biological Therapies: What Providers Need to Know
Nevada enacted a law in 2023 legalizing certain non-FDA-approved biological and gene therapies for patients who meet specified criteria, placing it among the early states, alongside Florida and Utah, to build a state framework around therapies the FDA has not approved. The specifics of what that law requires of providers are not cleanly documented in […]
California’s Stem Cell Disclosure Law: What Providers Operating in CA Must Post, Say, and Document
California was the first state in the country to require physicians to disclose the FDA status of stem cell therapy. SB 512, signed in 2017, added Section 684 to the Business and Professions Code and obligates any licensed practitioner who performs a non-FDA-approved stem cell therapy to post a notice, display it at the entrance, […]
IRB Approval vs. Investigational Status: Wyoming SF 48’s Two Pathways for Stem Cell Therapy
Wyoming’s Stem Cell Freedom Act, SF 48, lets a physician perform non-FDA-approved stem cell therapy only if, among other conditions, the therapy is conducted under a current Institutional Review Board approval or the stem cells qualify as an investigational drug, biological product, or device. Those are two distinct legal pathways, and the Act defines each […]
The Wyoming Stem Cell Freedom Act Takes Effect July 1, 2026: What Physicians Need to Know Now
Wyoming’s Stem Cell Freedom Act, Senate File 48, was passed during the 2026 budget session and signed into law. It creates a new article of the Wyoming statutes, W.S. 35-4-1101 through 35-4-1106, and it takes effect July 1, 2026. The Act authorizes physicians to recommend and perform certain non-FDA-approved stem cell therapies and shields a […]
Utah’s Stem Cell Disclosure Law: What Suppliers and Providers Both Must Do Under SB 275
Utah’s stem cell disclosure law lives in Section 58-1-512 of the Utah Code. It began as SB 199 in 2024, which required providers to give patients a written notice and obtain consent before performing non-FDA-approved stem cell therapy. SB 275, passed in the 2025 session, amended that section to add a new obligation aimed upstream […]
What Florida’s SB 1768 Means for Advertising Your Stem Cell Practice
Florida’s CS/CS/SB 1768 does not just regulate how physicians perform non-FDA-approved stem cell therapy. It regulates how they advertise it. The statute requires a specific notice in every advertisement, and that requirement sits on top of, not instead of, the Federal Trade Commission’s rules on health claims and testimonials and the advertising policies of Google […]
Florida SB 1768: The Complete Physician Compliance Checklist for Stem Cell Therapy
Florida’s CS/CS/SB 1768, codified at Sections 458.3245 and 459.0127 of the Florida Statutes and enacted as Chapter 2025-185, took effect July 1, 2025. It authorizes licensed Florida physicians to perform certain stem cell therapies that are not approved by the U.S. Food and Drug Administration, but only inside a narrow set of conditions that govern […]
The Adipose-Derived Stem Cell Market in 2026: Science, Pipeline, and What It Means for Patients Who Bank Today
The adipose-derived stem cell market is one of the most active segments in regenerative medicine in 2026, driven by over four hundred active clinical trials, the December 2024 FDA approval of the first MSC-based biologic, and a growing body of published research documenting the multipotent and immunomodulatory properties of ADSCs across orthopedic, autoimmune, neurological, and […]
Expanded Access Programs for Investigational Drugs: What Physicians and Patients Need to Know
Expanded access, also called compassionate use, is the FDA pathway that allows patients with serious or life-threatening conditions to access investigational drugs, biologics, or medical devices outside of a clinical trial when no comparable alternative therapy is available. The process requires the treating physician to submit a request to the FDA and obtain agreement from […]